Antibiotic compounds

Abstract

This invention relates to novel purified compounds of Formula I. The invention includes all stereoisomeric forms and all tautomeric forms of the compounds of Formula I and pharmaceutically acceptable salts and derivatives. The present invention further relates to processes for the production of the novel antibacterial compounds by fermentation of the microorganism belonging to Streptomyces species (PM0626271/MTCC 5447) and to pharmaceutical compositions containing one or more of the novel compounds as active ingredient and their use in medicines for treatment and prevention of diseases caused by bacterial infections.

1 - 19 . (canceled) 
     
     
         20 . An isolated compound selected from the compound of Formula I(a) or the compound of Formula I(b): 
       
         
           
           
               
               
           
         
         or a stereoisomer, or a tautomer, or a pharmaceutically acceptable salt thereof. 
       
     
     
         21 . The isolated compound as claimed in  claim 20 , wherein the compound is isolated from fermented broth of a microorganism belonging to  Streptomyces  species (PM0626271/MTCC 5447). 
     
     
         22 . The isolated compound of Formula I(a) as claimed in  claim 20 , wherein said compound is characterized by:
 (a) molecular weight of 1649.5,   (b) molecular formula C 71 H 83 N 19 O 18 S 5 ,   (c)  1 H NMR spectrum as depicted in  FIG. 1 , and   (d)  13 C NMR spectrum as depicted in  FIG. 2 .   
     
     
         23 . The isolated compound of Formula I(b) as claimed in  claim 20 , wherein said compound is characterized by:
 (a) molecular weight of 1651.5,   (b) molecular formula C 71 H 85 N 19 O 18 S 5 , and   (c)  1 H NMR spectrum as depicted in  FIG. 3 .   
     
     
         24 . A pharmaceutical composition comprising an effective amount of the isolated compound of Formula I(a) or the isolated compound of Formula I(b) as claimed in  claim 20  and at least one pharmaceutically acceptable excipient or carrier. 
     
     
         25 . The pharmaceutical composition as claimed in  claim 24 , wherein the pharmaceutical composition is in the form of a tablet, coated tablet, capsule, granule, powder cream, ointment, gel, emulsion, suspension, or solution for injection. 
     
     
         26 . A method of treating or preventing a bacterial infection comprising administering to a mammal in need thereof an effective amount of the isolated compound of Formula I(a) or the isolated compound of Formula I(b) as claimed in  claim 20 . 
     
     
         27 . The method as claimed in  claim 26 , wherein the bacterial infection is caused by bacteria belonging to  Staphylococcus, Streptococcus , Enterococci,  Bacillus  or  Mycobacterium  species. 
     
     
         28 . The method as claimed in  claim 27 , wherein the bacteria belonging to  Staphylococcus  species is methicillin-resistant, or vancomycin-resistant or both. 
     
     
         29 . The method as claimed in  claim 27 , wherein the bacteria belonging to Enterococci species is vancomycin-resistant. 
     
     
         30 . The method as claimed in  claim 27 , wherein the bacteria belonging to  Mycobacterium  species is multi drug-resistant.